Gelteq Limited (GELS)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Simon Hayden Szewach | Co-Founder & Executive Chairman | -- | -- | 1980 |
| Mr. Nathan Jacob Givoni | Co-Founder, CEO & Director | -- | -- | 1984 |
| Mr. Anthony W. Panther A.C.I.S., AGIA, B.E., C.A., L.L.B., LL.B | Chief Financial Officer | -- | -- | 1963 |
| Dr. Paul M. Wynne | Chief Scientific Officer | -- | -- | 1963 |
| Mr. Adam Bendell | President of U.S. Operations | -- | -- | -- |
| Mr. Matthew Jones | Head of Sports Performance | -- | -- | -- |
Gelteq Limited
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 7
Description
Gelteq Limited focuses on developing, testing, and commercializing white label gel-based delivery solutions for humans and animals in Asia-Pacific Region. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Caulfield, Australia.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
October 31, 2024 at 12:00 AM UTC
NT 20-F: Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F
September 26, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
September 24, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
June 28, 2024 at 12:00 AM UTC
POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
March 27, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission